Drug Profile
Icatibant inhalation
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class Analgesics; Antiarrhythmics; Antifibrotics; Cardiovascular therapies; Kinins; Neuropeptides; Oligopeptides; Vascular disorder therapies
- Mechanism of Action Bradykinin B2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 12 Sep 2007 Discontinued - Preclinical for Asthma in USA (Inhalation)
- 04 Sep 2007 Jerini regains commercialisation rights to icatibant inhalation for Asthma in USA and Canada